Literature DB >> 21159611

Detection of tumor response to a vascular disrupting agent by hyperpolarized 13C magnetic resonance spectroscopy.

Sarah E Bohndiek1, Mikko I Kettunen, De-en Hu, Timothy H Witney, Brett W C Kennedy, Ferdia A Gallagher, Kevin M Brindle.   

Abstract

Nuclear spin hyperpolarization can dramatically increase the sensitivity of the (13)C magnetic resonance experiment, allowing dynamic measurements of the metabolism of hyperpolarized (13)C-labeled substrates in vivo. Here, we report a preclinical study of the response of lymphoma tumors to the vascular disrupting agent (VDA), combretastatin-A4-phosphate (CA4P), as detected by measuring changes in tumor metabolism of hyperpolarized [1-(13)C]pyruvate and [1,4-(13)C(2)]fumarate. These measurements were compared with dynamic contrast agent-enhanced magnetic resonance imaging (DCE-MRI) measurements of tumor vascular function and diffusion-weighted MRI (DW-MRI) measurements of the tumor cell necrosis that resulted from subsequent loss of tumor perfusion. The rate constant describing flux of hyperpolarized (13)C label between [1-(13)C]pyruvate and lactate was decreased by 34% within 6 hours of CA4P treatment and remained at this lower level at 24 hours. The rate constant describing production of labeled malate from hyperpolarized [1,4-(13)C(2)]fumarate increased 1.6-fold and 2.5-fold at 6 and 24 hours after treatment, respectively, and correlated with the degree of necrosis detected in histologic sections. Although DCE-MRI measurements showed a substantial reduction in perfusion at 6 hours after treatment, which had recovered by 24 hours, DW-MRI showed no change in the apparent diffusion coefficient of tumor water at 6 hours after treatment, although there was a 32% increase at 24 hours (P < 0.02) when regions of extensive necrosis were observed by histology. Measurements of hyperpolarized [1-(13)C]pyruvate and [1,4-(13)C(2)]fumarate metabolism may provide, therefore, a more sustained and sensitive indicator of response to a VDA than DCE-MRI or DW-MRI, respectively. ©2010 AACR.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21159611      PMCID: PMC3003424          DOI: 10.1158/1535-7163.MCT-10-0706

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  33 in total

1.  Phase II trial of combretastatin A4 phosphate, carboplatin, and paclitaxel in patients with platinum-resistant ovarian cancer.

Authors:  M Zweifel; G C Jayson; N S Reed; R Osborne; B Hassan; J Ledermann; G Shreeves; L Poupard; S-P Lu; J Balkissoon; D J Chaplin; G J S Rustin
Journal:  Ann Oncol       Date:  2011-01-27       Impact factor: 32.976

Review 2.  Quantitative imaging biomarkers in the clinical development of targeted therapeutics: current and future perspectives.

Authors:  James P B O'Connor; Alan Jackson; Marie-Claude Asselin; David L Buckley; Geoff J M Parker; Gordon C Jayson
Journal:  Lancet Oncol       Date:  2008-08       Impact factor: 41.316

Review 3.  Targeting tumour vasculature: the development of combretastatin A4.

Authors:  J Griggs; J C Metcalfe; R Hesketh
Journal:  Lancet Oncol       Date:  2001-02       Impact factor: 41.316

4.  Effect of vascular targeting agent in rat tumor model: dynamic contrast-enhanced versus diffusion-weighted MR imaging.

Authors:  Harriet C Thoeny; Frederik De Keyzer; Vincent Vandecaveye; Feng Chen; Xihe Sun; Hilde Bosmans; Robert Hermans; Eric K Verbeken; Chris Boesch; Guy Marchal; Willy Landuyt; Yicheng Ni
Journal:  Radiology       Date:  2005-09-28       Impact factor: 11.105

5.  Preclinical evaluation of tumor microvascular response to a novel antiangiogenic/antitumor agent RO0281501 by dynamic contrast-enhanced MRI at 1.5 T.

Authors:  Manickam Muruganandham; Mihaela Lupu; Jonathan P Dyke; Cornelia Matei; Michael Linn; Kathryn Packman; Kenneth Kolinsky; Brian Higgins; Jason A Koutcher
Journal:  Mol Cancer Ther       Date:  2006-08       Impact factor: 6.261

6.  Navigated diffusion imaging of normal and ischemic human brain.

Authors:  A J de Crespigny; M P Marks; D R Enzmann; M E Moseley
Journal:  Magn Reson Med       Date:  1995-05       Impact factor: 4.668

7.  Production of hyperpolarized [1,4-13C2]malate from [1,4-13C2]fumarate is a marker of cell necrosis and treatment response in tumors.

Authors:  Ferdia A Gallagher; Mikko I Kettunen; De-En Hu; Pernille R Jensen; René In 't Zandt; Magnus Karlsson; Anna Gisselsson; Sarah K Nelson; Timothy H Witney; Sarah E Bohndiek; Georg Hansson; Torben Peitersen; Mathilde H Lerche; Kevin M Brindle
Journal:  Proc Natl Acad Sci U S A       Date:  2009-11-10       Impact factor: 11.205

8.  Detecting tumor response to treatment using hyperpolarized 13C magnetic resonance imaging and spectroscopy.

Authors:  Sam E Day; Mikko I Kettunen; Ferdia A Gallagher; De-En Hu; Mathilde Lerche; Jan Wolber; Klaes Golman; Jan Henrik Ardenkjaer-Larsen; Kevin M Brindle
Journal:  Nat Med       Date:  2007-10-28       Impact factor: 53.440

9.  Antitumor and antivascular effects of AVE8062 in ovarian carcinoma.

Authors:  Tae Jin Kim; Murali Ravoori; Charles N Landen; Aparna A Kamat; Liz Y Han; Chunhua Lu; Yvonne G Lin; William M Merritt; Nicholas Jennings; Whitney A Spannuth; Robert Langley; David M Gershenson; Robert L Coleman; Vikas Kundra; Anil K Sood
Journal:  Cancer Res       Date:  2007-10-01       Impact factor: 12.701

10.  Reproducibility and changes in the apparent diffusion coefficients of solid tumours treated with combretastatin A4 phosphate and bevacizumab in a two-centre phase I clinical trial.

Authors:  Dow-Mu Koh; Matthew Blackledge; David J Collins; Anwar R Padhani; Toni Wallace; Benjamin Wilton; N Jane Taylor; J James Stirling; Rajesh Sinha; Pat Walicke; Martin O Leach; Ian Judson; Paul Nathan
Journal:  Eur Radiol       Date:  2009-06-23       Impact factor: 5.315

View more
  35 in total

1.  Beyond antiangiogenesis: vascular modulation as an anticancer therapy-a review.

Authors:  Bryan T Oronsky; Jan J Scicinski; Tony Reid; Susan Knox
Journal:  Transl Oncol       Date:  2012-06-01       Impact factor: 4.243

2.  Metabolism of hyperpolarized [1-¹³C]pyruvate in the isolated perfused rat lung - an ischemia study.

Authors:  B Pullinger; H Profka; J H Ardenkjaer-Larsen; N N Kuzma; S Kadlecek; R R Rizi
Journal:  NMR Biomed       Date:  2012-02-07       Impact factor: 4.044

3.  Hyperpolarized Metabolic Imaging Detects Latent Hepatocellular Carcinoma Domains Surviving Locoregional Therapy.

Authors:  Nicholas R Perkons; Ryan M Kiefer; Michael C Noji; Mehrdad Pourfathi; Daniel Ackerman; Sarmad Siddiqui; David Tischfield; Enri Profka; Omar Johnson; Stephen Pickup; Anthony Mancuso; Austin Pantel; Michelle R Denburg; Gregory J Nadolski; Stephen J Hunt; Emma E Furth; Stephen Kadlecek; Terence P F Gade
Journal:  Hepatology       Date:  2020-05-16       Impact factor: 17.425

Review 4.  Novel Approaches to Imaging Tumor Metabolism.

Authors:  Sui-Seng Tee; Kayvan R Keshari
Journal:  Cancer J       Date:  2015 May-Jun       Impact factor: 3.360

5.  Hyperpolarized 13C Metabolic Magnetic Resonance Spectroscopy and Imaging.

Authors:  Eugen Kubala; Kim A Muñoz-Álvarez; Geoffrey Topping; Christian Hundshammer; Benedikt Feuerecker; Pedro A Gómez; Giorgio Pariani; Franz Schilling; Steffen J Glaser; Rolf F Schulte; Marion I Menzel; Markus Schwaiger
Journal:  J Vis Exp       Date:  2016-12-30       Impact factor: 1.355

Review 6.  MR Molecular Imaging of Brain Cancer Metabolism Using Hyperpolarized 13C Magnetic Resonance Spectroscopy.

Authors:  Chloé Najac; Sabrina M Ronen
Journal:  Top Magn Reson Imaging       Date:  2016-10

Review 7.  Dynamic nuclear polarisation: The future of imaging in oncology?

Authors:  Eva M Serrao; Kevin M Brindle
Journal:  Porto Biomed J       Date:  2017-02-10

8.  High-throughput hyperpolarized (13)C metabolic investigations using a multi-channel acquisition system.

Authors:  Jaehyuk Lee; Marc S Ramirez; Christopher M Walker; Yunyun Chen; Stacey Yi; Vlad C Sandulache; Stephen Y Lai; James A Bankson
Journal:  J Magn Reson       Date:  2015-09-05       Impact factor: 2.229

9.  Quantitative Evaluation of Tumor Early Response to a Vascular-Disrupting Agent with Dynamic PET.

Authors:  Ning Guo; Fan Zhang; Xiaomeng Zhang; Jinxia Guo; Lixin Lang; Dale O Kiesewetter; Gang Niu; Quanzheng Li; Xiaoyuan Chen
Journal:  Mol Imaging Biol       Date:  2015-12       Impact factor: 3.488

10.  Monitoring chemotherapeutic response by hyperpolarized 13C-fumarate MRS and diffusion MRI.

Authors:  Lionel Mignion; Prasanta Dutta; Gary V Martinez; Parastou Foroutan; Robert J Gillies; Bénédicte F Jordan
Journal:  Cancer Res       Date:  2013-11-27       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.